FDA Advisory Panels To See More Questions On Post-Market Safety Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
FDAAA authorities, such as REMS and the Safe Use initiative, direct FDA attention to appropriate use of drugs.
You may also be interested in...
Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree
Whether randomized controlled clinical trials or observational studies are best for measuring the risks of long acting beta-2 adrenergic agonists remains unresolved after a two-day FDA advisory committee meeting
Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree
Whether randomized controlled clinical trials or observational studies are best for measuring the risks of long acting beta-2 adrenergic agonists remains unresolved after a two-day FDA advisory committee meeting
Clinical Trials Or Observational Studies for Asthma? FDA Advisory Panels Can't Agree
FDA wants to gather long-term safety data in long acting beta-2 adrenergic agonist asthma drugs.